Genoskin raises $8.7M in Series A funding led by OCCTE to drive growth and expand its commercial presence.

Sep 16, 2025•15 days ago

Amount Raised

$8.7 Million

Round Type

series a

SalemBiotechnologyHealth Care

Investors

Crédit AgricoleCaisse D’epargne Midi PyrénéesBnp ParibasBpifranceCa Toulouse 31 InitiativesGso InnovationCaptech SantéOccte

Description

Genoskin, a Toulouse-based CRO, raised $8.7M in Series A funding. The round included a $5.4M equity investment led by OCCTE and $3.3M in structured bank debt from Bpifrance and local partners. The funds will support growth and staff recruitment over the next three years. Genoskin specializes in improving drug testing with ex vivo human skin platforms.

Company Information

Company

Genoskin

Location

Salem, Massachusetts, United States

About

Genoskin offers unmatched expertise in skin biology and immunology to support your research and drug development. Our mission is to generate reliable human data before regulatory studies for therapeutics, vaccines, medical devices, cosmetics, and chemicals. Using donated human skin, we preserve its viability for up to seven days post-surgery with our proprietary patented technology—allowing comprehensive testing across all cell types and skin structures. Unlike animal or engineered models, our platforms provide authentic, human-relevant data. With advanced assays, including imaging techniques and next-generation sequencing, combined with deep scientific expertise, we equip you with the data needed to accelerate your projects with confidence and precision.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns